Search results
Results From The WOW.Com Content Network
(Reuters) -Janux Therapeutics shares more than doubled in value on Tuesday after the drug developer reported encouraging interim early-stage data for its experimental therapy to treat an advanced ...
Key EGFR non-small cell lung cancer companies such as Cullinan Oncology, Suzhou Puhe Pharmaceutical Technology, Taiho Pharmaceutical, ORIC Pharmaceuticals, Nuvalent, Shanghai Junshi Biosciences, Janux Therapeutics, HK inno.N, Betta Pharmaceuticals, Bridge Biotherapeutics, Sorrento Therapeutics, Bayer, Avistone Pharmaceuticals, and others are ...
Jennifer Maynard is an American chemist who is the Henry Beckman Professor in Chemical Engineering at the University of Texas at Austin. Her research considers the development of therapeutic targets for infectious diseases. She was elected a Senior Member of the National Academy of Inventors in 2023.
www .bms .com. Juno Therapeutics Inc was an American biopharmaceutical company founded in 2013 through a collaboration of the Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and pediatrics partner Seattle Children's Research Institute. The company was launched with an initial investment of $120 million, with a ...
Athira Pharma Inc. Athira Pharma is a late clinical stage American biopharmaceutical company developing small molecules to restore neuronal health and stop the neurodegeneration brought on by diseases such as Alzheimer's disease and Parkinson's disease. The company's lead candidate, ATH-1017, is in human studies for Alzheimer's disease as of 2021.
The decision marks another hurdle for Minerva after the health regulator denied to review its initial marketing application for the drug in 2022. The FDA in its so-called "Complete Response Letter ...
Revenue. $324.1 Million (2019) [1] Number of employees. 225 (2011) Website. lexpharma .com. Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and ...
Xanomeline/trospium, also known under the brand name KarXT, is an investigational oral dual-drug fixed-dose combination of xanomeline and trospium. It is undergoing a phase 3 clinical trial for the treatment of schizophrenia. Xanomeline is a functionally preferring muscarinic M4 and M1 receptor agonist that readily passes into the central ...